Status:
TERMINATED
EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Lead Sponsor:
David Rizzieri
Collaborating Sponsors:
Eleos, Inc.
Conditions:
Lymphoma, Small Lymphocytic
Leukemia, Lymphocytic, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this research study is to see if the investigational drug EL625, when combined with traditional chemotherapy (rituximab, fludarabine, and cyclophosphamide), is effective in Persistent C...
Detailed Description
Chronic lymphocytic leukemia (CLL) and small B-cell lymphocytic lymphoma (SLL) are thought to be different manifestations of the same disease. Treatment options for CLL/SLL range from a watch and wait...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of CLL/SLL who have received at least one prior treatment regimen and have persistent disease (i.e. any evidence of active disease). Patients with a chromosome 17 abnormality or a p53 mutation of any type may be enrolled without having received prior treatment.
- Patients must be 18 years of age or older.
- Patient has an estimated or measured creatinine clearance ≥30 ml/min at study enrollment.
- AST, ALT, total bilirubin \< than 2.5 times the upper limit of normal.
- WBC \> 1.5; ANC \>500; Plt \>50,000 unless documented as due to disease
- ECOG performance status of 0-2.
- Voluntary written informed consent before performance of any study-related procedure not part of normal medical care.
- Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for 2 weeks after administration of the study drug.
- Male subject agrees to use an acceptable method for contraception for the duration of the study therapy and for 2 weeks after administration of study drug.
Exclusion
- Female who is pregnant or lactating.
- Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
- Patients with another malignancy within the last three years (from documentation of remission) other than basal or squamous cell skin cancer, resected early stage prostate cancer not requiring systemic treatment or CIS of the cervix or fully treated early stage prostate cancer.
- Significant cardiac or vascular events within 6 months: acute MI, unstable angina, severe peripheral vascular disease (ischemic pain at rest class 3 or worse, non-healing ulcers/wounds, congestive heart failure (NYHA class ≥ 2), uncontrolled cardiac arrhythmias, and disseminated intravascular coagulation.
- Patients who are unable to refrain from taking acetaminophen
- Investigational agent within 14 days of enrolling on the study.
- Patients unable or unwilling to refrain from antioxidants including vitamin A, vitamin C, vitamin E, lycopene, lutein, grape seed extract, pycnogenol, green tea extract, and the like.
- Patients who have received a prior allogenic stem cell transplant and have at least 2.5% donor cells still evident on engraftment studies.
Key Trial Info
Start Date :
February 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2012
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00636155
Start Date
February 1 2008
End Date
May 1 2012
Last Update
November 28 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Medical Center
Durham, North Carolina, United States, 27710